The onset location of multiple sclerosis predicts the location of subsequent relapses

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 80, Issue 4, 2009, Pages 400-403

  Mowry, E M ^a,d   Deen, S ^a   Malikova, I ^b   Pelletier, J ^b   Bacchetti, P ^c   Waubant, E ^a  

^a UCSF Multiple Sclerosis Center   (United States)

^b Marseille Multiple Sclerosis Center   (France)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BRAIN STEM; CEREBELLUM; DISEASE EXACERBATION; HUMAN; LOGISTIC REGRESSION ANALYSIS; MULTIPLE SCLEROSIS; OPTIC NERVE; PREDICTION; PREDICTOR VARIABLE; PRIORITY JOURNAL; RECURRENT DISEASE; SPINAL CORD; ADULT; BRAIN; COHORT ANALYSIS; DEMYELINATING DISEASE; FEMALE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; PATHOLOGY; PROSPECTIVE STUDY; RISK;

ADULT; AGE OF ONSET; BRAIN; BRAIN STEM; CEREBELLUM; COHORT STUDIES; DEMYELINATING DISEASES; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; ODDS RATIO; OPTIC NERVE; PROSPECTIVE STUDIES; RECURRENCE; SPINAL CORD;

EID: 64749095798     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2008.157305     Document Type: Article

References (23)

1. Bautista JF, Kelly JA, Harley JB, et al. Addressing genetic heterogeneity in complex disease: finding seizure genes in systemic lupus erythematosus. Epilepsia 2008;49:527-30.
2. Bouali H, Nietert P, Nowling TM, et al. Association of the G-463A myeloperoxidase gene polymorphism with renal disease in African Americans with systemic lupus erythematosus. J Rheumatol 2007;34:2028-34.
3. Namjou B, Kilpatrick J, Harley JB. Genetics of clinical expression in SLE. Autoimmunity 2007;40:602-12.
4. Heinlen LD, McClain MT, Merrill J, et al. Clinical criteria for systemic lupus erythematosus precede diagnosis, and associated autoantibodies are present before clinical symptoms. Arthritis Rheumatism 2007;56:2344-51.
5. Lucchinetti CF, Bruck W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000;47:707-17.
6. Barcellos LF, Oksenberg JR, Green AJ, et al. Genetic basis for clinical expression in multiple sclerosis. Brain 2002;125:150-8.
7. Deen S, Bacchetti P, High A, et al. Predictors of the location of multiple sclerosis relapse. J Neurol Neurosurg Psychiatry 2008;79:1190-3.
8. West T, Wyatt M, High A, et al. Are initial demyelinating event recovery and time to second event under differential control? Neurology 2006;67:809-13.
9. Mowry EM, Pesic M, Grimes B, et al. Demyelinating events in early multiple sclerosis have inherent severity and recovery. Neurology. In press.
10. Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;66:1485-9.
11. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel of the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-7
12. Confavreux C. Establishment and use of multiple sclerosis registers-EDMUS. Ann Neurol 1994;36:136-9S.
13. Comi G, Filippi M, Wolinsky J. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol 2001;49:290-7.
14. Waubant E, Goodkin DE, Sloan R, et al. A pilot study of MRI activity before and during interferon beta-1a therapy. Neurology 1999;53:874-6.
15. Kira J. Multiple sclerosis in the Japanese population. Lancet Neurol 2003;2:117-27.
16. Yamasaki K, Horiuchi I, Minohara M, et al. HLA-DPB1 0501-associated opticospinal multiple sclerosis. Brain 1999;122:1689-96.
17. Kira J, Yamasaki K, Horiuchi I, et al. Changes in the clinical phenotypes of multiple sclerosis during the past 50 years in Japan. J Neurol Sci 1999;166:53-7.
18. Fukazawa T, Yamasaki K, Ito H, et al. Both the HLA-DPB1 and -DRB1 alleles correlate with risk for multiple sclerosis in Japanese: clinical phenotypes and gender as important factors. Tissue Antigens 2000;55:199-205.
19. Berger T, Weerth S, Kojima K, et al. Experimental autoimmune encephalomyelitis: the antigen specificity of T-lymphocytes determines the topography of lesions in the central and peripheral nervous system. Lab Invest 1997;76:355-64.
20. Butterfield RJ, Blankenhorn EP, Roper RJ, et al. Identification of genetic loci controlling the characteristics and severity of brain and spinal cord lesions in experimental allergic encephalomyelitis. Am J Pathol 2000;157:637-45.
21. Bettelli E, Pagany M, Weiner HL, et al. Myelin oligodendrocyte glycoprotein-specific T cell receptor transgenic mice develop spontaneous autoimmune optic neuritis. J Exp Med 2003;197:1073-81.
22. Krishnamoorthy G, Lassmann H, Wekerle H, et al. Spontaneous opticospinal encephalomyelitis in a double-transgenic mouse model of autoimmune T cell/B cell cooperation. J Clin Invest 2006;116:2385-92.
23. Stromnes IM, Cerretti LM, Liggitt D, et al. Differential regulation of central nervous system autoimmunity by Th1 and Th17 cells. Nat Med 2008;14:337-42.